


Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.							Date	Name	Class	Subclass	Filing Date if Appropriate
<input checked="" type="checkbox"/>	5	9	4	5	4	1	1	Aug. 31, 1999	Larson et al.	514	171	
<input checked="" type="checkbox"/>	5	8	6	3	5	5	0	Jan. 26, 1999	Maeda et al.	424	423	
<input checked="" type="checkbox"/>	5	8	5	8	9	9	8	Jan. 12, 1999	Leuschner	514	171	
<input checked="" type="checkbox"/>	5	8	4	6	9	6	4	Dec. 08, 1998	Ozeki	514	182	
<input checked="" type="checkbox"/>	5	8	4	3	9	2	9	Dec. 1, 1998	Larson et al.	514	182	
<input checked="" type="checkbox"/>	5	6	8	6	5	8	8	Nov. 11, 1997	Yoo			
<input checked="" type="checkbox"/>	5	6	5	3	9	8	7	Aug. 5, 1997	Modi et al.	424	400	
<input checked="" type="checkbox"/>	5	6	4	1	7	6	7	Jun. 24, 1997	Wess et al.			
<input checked="" type="checkbox"/>	5	5	7	8	3	0	4	Nov. 26, 1996	Sipos	424	94.1	
<input checked="" type="checkbox"/>	5	5	3	4	5	0	5	Jul. 9, 1996	Widauer	514	169	
<input checked="" type="checkbox"/>	5	4	8	4	7	7	6	Jan. 16, 1996	Racz et al.	514	54	
<input checked="" type="checkbox"/>	5	4	7	0	5	8	1	Nov. 28, 1995	Grillo et al.	424	479	
<input checked="" type="checkbox"/>	5	4	4	6	0	2	6	Aug. 29, 1995	Ruff et al.	514	15	
<input checked="" type="checkbox"/>	5	3	8	0	5	3	3	Jan. 10, 1995	Egidio et al.	424	456	
<input checked="" type="checkbox"/>	5	3	2	4	5	1	4	Jun. 28, 1994	Sipos	424	94.63	
<input checked="" type="checkbox"/>	5	3	1	0	5	6	0	May 10, 1994	Widauer	424	451	
<input checked="" type="checkbox"/>	5	3	0	2	4	0	0	Apr. 12, 1994	Sipos	424	494	
<input checked="" type="checkbox"/>	5	3	0	2	3	9	8	Apr. 12, 1994	Egidio et al.	424	474	
<input checked="" type="checkbox"/>	5	3	0	0	3	0	0	Apr. 5, 1994	Egidio et al.	424	456	
<input checked="" type="checkbox"/>	5	2	6	0	0	7	4	Nov. 9, 1993	Sipos	424	497	
<input checked="" type="checkbox"/>	5	1	5	7	0	2	2	Oct. 20, 1992	Barbul	514	18	

Examiner

Date Considered

12/24/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



*	W	5	1	4	9	5	3	7	Sep. 22, 1992	Azria et al.	424	436	
*		5	0	5	7	3	2	1	Oct. 15, 1991	Edgren et al.	424	413	
*		4	6	8	1	8	7	6	Jul. 21, 1987	Marples et al.	514	182	
		4	5	8	5	7	9	0	Apr. 29, 1986	Padfield et al.	514	471	
*		4	3	2	7	7	2	5	May 4, 1982	Cortese et al.	128	260	
		4	3	2	0	1	4	6	Mar. 16, 1982	Walser	424	319	
*		3	9	1	6	8	9	9	Nov. 4, 1975	Theeuwes et al.	128	260	
*		3	8	4	5	7	7	0	Nov. 5, 1974	Theeuwes et al.	128	260	

FOREIGN PATENT DOCUMENT

		Document No.							Date	Country	Class	SubClass	Translator	
													Yes	No
		0	3	1	2	0	5	2	04/19/89	EPO-A1				
*		6	2	1	5	3	2	2	07/08/87	JP-A (Machine-Assisted Translation)				
*		5	5	0	2	2	6	1	02/18/80	JP-A (Machine-Assisted Translation)				

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

		Graham et al., "H. pylori in the Pathogenesis of Duodenal Ulcer: Interaction Between Duodenal Acid Load, Bile, and H. pylori", American Journal of Gastroenterology (2000), Vol. 95, No. 1, pp.87-91.
*		Hammad et al., "Solubility and Stability of Lorazepam in Bile Salt/Soya Phosphatidylcholine-Mixed Micelles", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (1999) Vol. 25, No. 4, pp. 409-417.
		Itoh et al. "The interaction of bile acids and Helicobacter pylori", J. GASTROENTEROL (1999), 34:653-654.

Examiner

Date Considered

12/14/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



Invernizzi et al., "Differences in the Metabolism and Disposition of Ursodeoxycholic Acid and of its Taurine-Conjugated Species in Patients with Primary Biliary Cirrhosis", HEPATOLOGY, (1999) Vol. 29, No. 2 pp. 320-327.

Itoh et al., "Antibacterial action of bile acids against *Helicobacter pylori* and changes in its ultrastructural morphology: effect of unconjugated dihydroxy bile acid", J. GASTROENTEROL, (1999) 34:571-576.

Knopp et al., "Long-Term Blood Cholesterol-Lowering Effects of a Dietary Fiber Supplement", Am J Pre. Med (1999) 17(1):18-23.

* F. Lanzarotto et al., "Effect of Long-Term Simvastatin Administration as an Adjunct to Ursodeoxycholic Acid: Evidence for a Synergistic Effect on Biliary Bile Acid Composition but Not on Serum Lipids in Humans", GUT, (1999) Vol. 4 pp. 552-556.

* Leuschner et al., "Oral Budesonide and Ursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: Results of a Prospective Double-Blind Trial", GASTROENTEROLOGY, (1999) Vol. 117 pp. 918-925.

* Na et al., "Cloud Point of Nonionic Surfactants: Modulation with Pharmaceutical Excipients", PHARMACEUTICAL RESEARCH, (1999) Vol. 16, No. 4 pp. 562-568.

Osato et al., "Osmotic Effect of Honey on Growth and Viability of *Helicobacter pylori*", DIGESTIVE DISEASES AND SCIENCES, (1999) Vol. 44, No. 3 pp. 462-464.

* Sinisalo et al., "Ursodeoxycholic Acid and Endothelial-Dependent, Nitric Oxide-Independent Vasodilatation of Forearm Resistance Arteries in Patients with Coronary Heart Disease", BR. J. CLIN. PHARMACOL., (1999) Vol. 47 pp. 661-665.

* Verrips et al., "Effect of Simvastatin in Addition to Chenodeoxycholic Acid in Patients with Cerebrotendinous Xanthomatosis", METABOLISM, (1999) Vol. 48, No. 2 pp. 233-238.

* Wacker Biochem. Corp., advertisement, C&EN, 31 (April 12, 1999).

* M. A. Hammad, B. W. Müller, "Increasing Drug Solubility by Means of Bile Salt-Phosphatidylcholine-Based Mixed Micelles, EUROPEAN J. OF PHARMACEUTICS AND BIOPHARMACEUTICS, (1998) Vol. 46 pp. 361-367.

* M. A. Hammad et al., "Solubility and Stability of Tetrazepam in Mixed Micelles", EUROPEAN J. OF PHARMACEUTICAL SCIENCES, (1998) Vol. 7 pp. 49-55.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



Oliva et al., "Ursodeoxycholate Alleviates Alcoholic Fatty Liver Damage in Rats", ALCOHOL CLIN EXP RES., (1998), Vol. 22, No. 7, pp. 1538-1543.

Rodrigues et al., "Ursodeoxycholic Acid May Inhibit Deoxyxholic Acid-Induced Apoptosis by Modulating Mitochondrial Transmembrane Potential and Reactive Oxygen Species Production", MOLECULAR MEDICINE (1998) 4: 165-178.

Invernizzi et al., "Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo", Am J Physiol (1997) 273:G131-138,

Shinya Nagamatsu, "Phase I Clinical Study of Ursodesoxycholic Acid ", JPN. PHARMACOL. THER., (1997) Vol. 25, No. 6 pp. 145-159.

Keith D. Lindor, M.D., "Ursodiol For Primary Sclerosing Cholangitis", The New England Journal of Medicine, (1997) Vol. 336, No. 10., pp. 691-695.

Binek et al., "Bedeutung von Ursodeoxycholsäure bei der Eradikation von *Helicobacter pylori*", Schweiz Med Wochenschr (1996) 126 (Suppl. 79): 44S-46S.

Crosignani, et al., "Clinical Pharamcokinetics of Therapeutic Bile Acids", CLIN. PHARMACOKINET, (1996) Vol. 30, No. 5 pp. 333-358.

Han et al., "The Interaction of pH, Bile and *Helicobacter pylori* May Explain Duofenial Ulcer", American Journal of Gastroenterology (1996) Vol. 91, No. 6, pp. 1135-1137.

Mohler et al., "Effect of Ursodeoxycholic Acid on HCV Replication in Subtyped Chronic Hepatitis C", Digestive Diseases and Sciences, (1996) Vol 41, No. 6 p. 1276.

Newman et al., "Starch", ANALYTICAL PROFILES OF DRUG SUBSTANCES, (1996) Bristol-Myer Squibb Pharmaceutical Research Institute, New Brunswick, NJ, pp. 523-577.

Nishigaki, et al., "Ursodeoxycholic Acid Corrects Defective Natural Killer Activity by Inhibiting Prostaglandin E₂ Production in Primary Biliary Cirrhosis", Digestive Diseases and Sciences, (1996) Vol. 41, No. 7, pp. 1487-1493.

Panini et al., "The Influence of 2-Hydroxypropyl- β -Cyclodextrin on the Haemolysis Induced by Bile Acids", J. PHARM. PHARMACOL., (1996) Vol. 48 pp. 641-644.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



Tanaka et al., "Ligand-Independent Activation of the Glucocorticoid Receptor by Ursodeoxycholic Acid", The Journal of Immunology (1996) 156:1601-1608.

* Buckley et al., "Controlled Release Drugs in Overdose Clinical Consideration", DRUG SAFETY (1996) Vol. 12, No. 1 pp. 73-84.

* Jorgensen et al., "Characterisation of patients with a complete biochemical response to ursodeoxycholic acid", GUT (1995) 36:935-938, .

Klumra et al., "A 1-h Topical Therapy for the Treatment of *Helicobacter pylori* Infection", Am. J. Gastroenterol. (1995) Vol. 90, No. 1, pp.60-63.

* Lindor et al., "The Combination of Ursodeoxycholic Acid and Methotrexate for Patients with Primary Biliary Cirrhosis: The Results of a Pilot Study", HEPATOLOGY (1995) Vol. 22, No. 4 pp. 1158-1162.

* Rodrigues et al., "The Site-Specific Delivery of Ursodeoxycholic Acid to the Rat Colon by Sulfate Conjugation", GASTROENTEROLOGY (1995) Vol. 109 pp. 1835-1844.

* Simoni et al., "Bioavailability Study of a New, Sinking, Enteric-Coated Ursodeoxycholic Acid Formulation", PHARMACOLOGICAL RESEARCH (1995) Vol. 31, No. 2 pp. 115-119.

P.J. Sinko, "Utility of Pharmacodynamic Measures for Assessing the Oral Bioavailability of Peptides. 1. Administration of Recombinant Salmon Calcitonin in Rats", Journal of Pharmaceutical Sciences, (1995) Vol. 84, No. 11, pp.1374-1378.

* A. Benjamin Suttle and Kim L. R. Brouwer, "Regional Gastrointestinal Absorption of Ranitidine in the Rat", PHARMACEUTICAL RESEARCH, (1995) Vol. 12, No. 9 pp. 1311-1315.

* R. Panini et al., "Improvement of Ursodeoxycholic Acid Bioavailability by 2-Hydroxypropyl- β -Cyclodextrin Complexation in Healthy Volunteers", PHARMACOLOGICAL RESEARCH, (1995) Vol. 31, No. 314 pp. 205-209.

* "Pharmaceutical Necessities", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, Mack Printing Co., Easton, Pennsylvania (1995) pp. 1409-1410.

Angelin et al., "Effects of Ursodeoxycholic Acid on Plasma Lipids", Scand J. Gastroenterol. (1994) 29 Suppl 204:24-26.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614

I. Björkhem, "Inborn Errors of Metabolism with Consequences for Bile Acid Biosynthesis: A Minireview", Scand J. Gastroenterol (1994) 29 Suppl. 204:68-72.

A. Björkland and T.H. Totterman, "Is Primary Biliary Cirrhosis an Autoimmune Disease?", Scand J. Gastroenterol (1994) 29 Suppl. 204:32-9.

Boberg et al., "Etiology and Pathogenesis in Primary Sclerosing Cholangitis", Scand J. Gastroenterol (1994) 29 Suppl. 204:47-58.

Cirillo N.W. and F.R. Zwas., "Ursodeoxycholic Acid in the Treatment of Chronic Liver Disease", Am J Gastroenterol (1994) Vol. 89, No. 9 pp.1447-1452.

K. Einarsson, "Effect of Ursodeoxycholic Acid on Hepatic Cholesterol Metabolism", Scand J. Gastroenterol (1994) 29 Suppl. 204:19-23.

* Kurt Einarsson, Ed., "Treatment with Ursodeoxycholic Acid in Clinical Hepatology", PROCEEDINGS OF A WORKSHOP HELD 3 AND 4 FEBRUARY 1994 IN GÖTEBORG, SWEDEN, Scandinavian University Press (1994) pp. 1-72.

S. Friman and J Svarik, "A Possible Role of Ursodeoxycholic Acid in Liver Transplantation", Scand J. Gastroenterol (1994) 29 Suppl. 204:62-4.

A.F. Hofmann, "Pharmacology of Ursodeoxycholic Acid, an Enterohepatic Drug", Scand J. Gastroenterol (1994) 29 Suppl. 204:1-15.

U. Leuschner et al., "Ursodeoxycholic Acid Therapy in Primary Biliary Cirrhosis", Scand J. Gastroenterol (1994) 29 Suppl. 204:40-6.

Lindor et al., "Ursodeoxycholic Acid in the Treatment of Primary Biliary Cirrhosis", Scand J. Gastroenterol (1994) 106:1284-1290.

McLeod et al., "Glucocorticoid-Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Hydrolysis in Rat Gastrointestinal Tract Contents", J. Pharm Sci., (1994) Vol. 83, No. 9., pp. 1284-1288.

* McLeod et al., "Glucocorticoid-Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Steady-State Pharmacokinetics in the Rat", BIOPHARMACEUTICS & DRUG DISPOSITION, (1994) Vol. 15 pp. 151-161.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614

Paumgartner et al., "Ursodeoxycholic Acid Treatment of Cholesterol Gallstone Disease", Scand J. Gastroenterol (1994) 29 Suppl 204: 28-31.

Poupon, et al., "Ursodiol For the Long-Term Treatment of Primary Biliary Cirrhosis", The New England Journal of Medicine, (1994) Vol. 330, No. 19, pp.1342-1347.

* Roda et al., "Improved Intestinal Absorption of an Enteric-Coated Sodium Ursodeoxycholate Formulation", PHARMACEUTICAL RESEARCH, (1994) Vol. 11, No. 5 pp. 642-647.

Roda et al., "Influence of Ursodeoxycholic Acid on Biliary Lipids", Scand J Gastroenterol (1994) 29 Suppl. 204:16-8.

A. Stiehl, "Ursodeoxycholic Acid Therapy in Treatment of Primary Sclerosing Cholangitis", Scand J Gastroenterol (1994) 29 Suppl. 204:59-61.

Strandvik et al., "Cystic Fibrosis: Is Treatment with Ursodeoxycholic Acid of Value?", Scand J Gastroenterol (1994) 29 Suppl. 204:65-7.

* McLeod et al., "Synthesis and Chemical Stability of Glucocorticoid-Dextran Esters: Potential Prodrugs for Colon-Specific Delivery", INTERNATIONAL J. OF PHARMACEUTICS, (1993) Vol. 92 pp. 105-114.

* Gerrit H. P. Te Wierik et al., "Preparation, Characterization, and Pharmaceutical Application of Linear Dextrins, I. Preparation and Characterization of Amylodextrin, Metastable Amylodextrins, and Metastable Amylose", PHARMACEUTICAL RESEARCH, (1993) Vol. 10, No. 9 pp. 1274-1279.

* Gerrit H. P. Te Wierik et al., "Preparation, Characterization, and Pharmaceutical Application of Linear Dextrins. II. Complexation and Dispersion of Drugs with Amylodextrin by Freeze-Drying and Kneading", PHARMACEUTICAL RESEARCH, (1993) Vol. 10, No. 9 pp. 1280-1284.

* G. H. P. Te Wierik et al., "Preparation, Characterization and Pharmaceutical Application of Linear Dextrins: IV. Drug Release from Capsules and Tablets Containing Amylodextrin", INTERNATIONAL J. OF PHARMACEUTICS, (1993) Vol. 98 pp. 219-224.

* Scott L. Myers et al., "Solid-State Emulsions: The Effects of Maltodextrin on Microcrystalline Aging", PHARMACEUTICAL RESEARCH, (1993) Vol. 10, No. 9 pp. 1389-1391.

* Dressman et al., "Gastrointestinal Parameters that Influence Oral Medications", J. OF PHARMACEUTICAL SCIENCES, (1993) Vol. 82, No. 9 pp. 857-872.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614

- | | | |
|---|--|--|
| * | | Thorsteinn Loftsson et al., "The Effect of Cyclodextrins on the Solubility and Stability of Medroxyprogesterone Acetate and Megestrol Acetate in Aqueous Solution", INTERNATIONAL J. OF PHARMACEUTICS, (1993) Vol. 98 pp. 225-230. |
| | | Beuers et al., "Ursodeoxycholic Acid for Treatment of Primary Sclerosing Cholangitis: A Placebo-controlled Trial", Hepatology. (1992) Vol. 16, No. 3, pp.707-714. |
| | | Bode et al., "Polymorphism in <i>Helicobacter pylori</i> - a key function in recurrence of infection", Medizinische Klinik, (1992) 87(4):179-84. |
| * | | Colombo et al., "Ursodeoxycholic Acid Therapy in Cystic Fibrosis-associated Liver Disease: A Dose-response Study", HEPATOLOGY, (1992) Vol. 16, No. 4 pp. 924-930. |
| * | | De Caprio et al., "Bile Acid and sterol solubilization in 2-hydroxypropyl- β -cyclodextrin", Journal of Lipid Research, (1992) Vol. 33, pp. 441-443. |
| | | Fried et al., "Ursodeoxycholic Acid Treatment of Refractory Chronic Graft-versus-Host Disease of the Liver", Annals of Internal Medicine, (1992) 116:624-629. |
| * | | Walker et al., "Intestinal Absorption of Ursodeoxycholic Acid in Patients With Extrahepatic Biliary Obstruction and Bile Drainage", Gastroenterology (1992) 102:810-815. |
| | | M.L. Hanninen, "Sensitivity of <i>Helicobacter pylori</i> to Different Bile Salts", Eur. J. Clin. Microbiol. Infect., (1991) Vol. 10, pp.515-518. |
| | | Mathai et al., "The effect of bile acids on the growth and adherence of <i>Helicobacter pylori</i> ", Aliment Pharmacol Therap. (1991) 5, pp.653-668. |
| | | Rolandi et al., "Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis", Eur J. Clin Pharmacol (1991) 40:473-476. |
| * | | Tan et al., "Studies on Complexation between β -Cyclodextrin and Bile Salts", INTERNATIONAL J. PHARMACEUTICS, (1991) Vol. 74 pp. 127-135. |
| | | G. Buck, "Campylobacter pylori and Gastrointestinal Disease". Clinical Microbiology Reviews, (1990) Vol 3, No. 1 pp. 1-12. |

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



Chazouilleres et al., "Ursodeoxycholic Acid for Primary Sclerosing Cholangitis", J. HEPATOLOGY, (1990) Vol. 11 pp. 120-123.

Colombo et al., "Effects of Ursodeoxycholic Acid Therapy for Liver Disease Associated with Cystic Fibrosis", J. OF PEDIATRICS, (1990) Vol. 117, No. 3 pp. 482-489.

M. Y. Morgan, "Branched Chain Amino Acids in the Management of Chronic Liver Disease Facts and Fantasies", J. OF HEPATOLOGY, (1990) Vol. 11 pp. 133-141.

Podda et al., "Effect of Different Doses of Ursodeoxycholic Acid in Chronic Liver Disease", Digestive Diseases and Sciences, (1989) Vol. 34, No. 12, Suppl. pp.59S-65S.

Aigner A and Bauer A, "Bile acids, Long known active substances with a future", Med Monatsschr Pharm (1988) (11): 369-75.

Dioguardi et al., "The role of oral branched-chain amino acids (BCAAs) in the elevation of plasma ammonia (pNH₃)", Chapter 68, in ADVANCES IN AMMONIA METABOLISM AND HEPATIC ENCEPHALOPATHY, Soeters et al., eds., (1988) Elsevier Science Publishers B.V., pp.527-533.

Montanari et al., "Oral administration of branched-chain amino acids (BCAAs) in liver cirrhosis (LC): effect on their intra- and extracellular pools", Chapter 67, in ADVANCES IN AMMONIA METABOLISM AND HEPATIC ENCEPHALOPATHY, Soeters et al., eds., (1988) Elsevier Science Publishers B.V., pp.519-526.

N.F.H. Ho, "Utilizing Bile Acid Carrier Mechanisms to Enhance Liver and Small Intestine Absorption", Annals New York Academy of Sciences, (1987) 507:315-29.

Fiaccadori et al., "The effect of dietary supplementation with branch-chain amino acids (BCAAs) vs. casein in patients with chronic recurrent portal systemic encephalopathy: a controlled trial", pp.489-497. (1988) Elsevier Science Publishers B.V. Advances in ammonia metabolism and hepatic encephalopathy.

D.S. Tompkins and AP West. "Campylobacter pylori, acid and bile", J. Clin. Pathol. (1987) 40:1387.

Van Caekenbergh et al., "In Vitro Synergistic Activity between Bismuth Subcitrate and Various Antimicrobial Agents against Campylobacter pyloridis", ANTIMICROBIAL AGENT AND CHEMOTHERAPY, (1987) Vol. 31, No. 9, pp.1429-1430.

Miyajima et al., "Interaction of β -Cyclodextrin with Bile Salts in Aqueous Solutions", CHEM. PHARM. BULL., (1986) Vol. 34, No. 3 pp. 1395-1398.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



Golub et al., "Physiologic Considerations in Drug Absorption from the Gastrointestinal Tract", J. ALLERGY CLIN. IMMUNOL., (1986) Vol. 78, No. 4, Part 2 pp. 689-694.

* Gordon et al., "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts", PROC. NATL. ACAD. SCI., (1985) Vol. 82 pp. 7419-7423.

* Parquet et al., "Bioavailability, Gastrointestinal Transit, Solubilization and Faecal Excretion of Ursodeoxycholic Acid in Man", EUROPEAN J. OF CLINICAL INVESTIGATION, (1985) Vol. 15 pp. 171-178.

Stefaniwsky et al., "Ursodeoxycholic Acid Treatment of Bile Reflux Gastritis", GASTROENTEROLOGY (1985) Vol. 89, pp. 1000-1004.

* K. Müller, "Structural Aspects of Bile Salt-Lecithin Mixed Micelles", HEPATOLOGY, (1984) Vol. 4, No. 5 pp. 134S-137S.

* Murakami et al., "Effect of Bile Salts on the Rectal Absorption of Sodium Ampicillin in Rats", CHEM. PHARM. BULL., (1984) Vol. 32, No. 5 pp. 1948-1955.

* Zentler-Munro et al., "Effect of Intrajejunal Acidity on Aqueous Phase Bile Acid and Lipid Concentrations in Pancreatic Steatorrhoea Due to Cystic Fibrosis", GUT (1984) Vol. 25 pp. 500-507.

* Moses et al., "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol Effectiveness and Reproducibility in Normal and Diabetic Subjects", DIABETES, (1983) Vol. 32 pp. 1040-1047.

* Ziv et al., "Bile Salts Facilitate the Absorption of Heparin from the Intestine", BIOCHEMICAL PHARMACOLOGY, (1983) Vol. 32, No. 5 pp. 773-776.

* Armstrong et al., "The Hydrophobic-Hydrophilic Balance of Bile Salts. Inverse Correlation between Reverse-Phase High Performance Liquid Chromatographic Mobilities and Micellar Cholesterol-Solubilizing Capacities", J. LIPID RESEARCH, (1982) Vol. 23 pp. 70-80.

* Podda et al., "Gallstone Dissolution After 6 Months of Ursodeoxycholic Acid (UDCA): Effectiveness of Different Doses", J. INT. MED. RES., (1982) Vol. 10 pp. 59-63.

* Hirai et al., "Effect of Surfactants on the Nasal Absorption of Insulin in Rats", INTERNATIONAL J. OF PHARMACEUTICS, (1981) Vol. 9 pp. 165-172.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
APAP31191-A
072852.0117

Serial No.
09/778,154

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Yoo, S.

Filing Date
February 5, 2001

Group
1614



*			Hirai et al., "Mechanisms for the Enhancement of the Nasal Absorption of Insulin by Surfactants", INTERNATIONAL J. PHARMACEUTICS, (1981) Vol. 9 pp. 173-184.
*			Hollander et al., "Intestinal Absorption of Aspirin, Influence of pH, Taurocholate, Ascorbate and Ethanol", J. LAB. CLIN. MED., (1981) Vol. 98, No. 4 pp. 591-595.
*			Reynier et al., "Comparative Effects of Cholic, Chenodeoxycholic, and Ursodeoxycholic Acids on Micellar Solubilization and Intestinal Absorption of Cholesterol", J. LIPID RESEARCH, (1981) Vol. 22 pp. 467-473.
*			Igimi et al., "pH-Solubility Relations of Chenodeoxycholic and Ursodeoxycholic Acids: Physical-Chemical Basis for Dissimilar Solution and Membrane Phenomena", J. LIPID RESEARCH, (1980) Vol. 21 pp. 72-90.
*			Carey et al., "Micelle Formation by Bile Salts", Arch Intern Med, (1972) Vol. 130, pp.506-527.
*			Matthew J. Mollan, Jr. et al., "One of Aqueous Soluble Starch Conversion Products", MALTODEXTRIN, N/D, pp. 308-349. <i>Year?</i>
*			"MALTRIN® Maltodextrins & Corn Syrup Solids Chemical and Physical Properties", GPC Technical Bulletin, TB31-021296, Grain Processing Corp., Muscatine, Iowa, N/D, Brochure + 4 pages.
*			"Saccharide Composition Typical Carbohydrate Profiles", GPC Technical Bulletin TB30-021296, Grain Processing Corp., Muscatine, Iowa, N/D, 1 page.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.